FDA approves expanded use of Humira

Abbott Laboratories has won expanded approval of its rheumatoid arthritis drug Humira. Humira is now approved for psoriatic arthritis and as a front-line RA therapy. The drug targets a misdirected immune response in which healthy tissue is attacked, inducing skin inflammation, swelling and pain.

- read this AP article for more

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.